Patents Assigned to Celera Corporation
-
Patent number: 8071291Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: March 13, 2009Date of Patent: December 6, 2011Assignee: Celera CorporationInventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
-
Patent number: 8071302Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: September 20, 2010Date of Patent: December 6, 2011Assignee: Celera CorporationInventor: Hongjin Huang
-
Patent number: 8039212Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: November 4, 2008Date of Patent: October 18, 2011Assignee: Celera CorporationInventors: Yonghong Li, Hongjin Huang
-
Patent number: 7998689Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: GrantFiled: September 10, 2009Date of Patent: August 16, 2011Assignee: Celera CorporationInventors: Elizabeth Joseloff, Steve Ruben, Tao He, Yeounjin Kim
-
Patent number: 7993833Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: August 31, 2007Date of Patent: August 9, 2011Assignee: Celera CorporationInventors: Ann Begovich, Ellen Beasley, Michele Cargill, Steven Schrodi
-
Patent number: 7977052Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular stenosis and MI and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: March 13, 2006Date of Patent: July 12, 2011Assignee: Celera CorporationInventors: May M. Luke, James J. Devlin, Dov Shiffman
-
Patent number: 7960100Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: GrantFiled: March 17, 2008Date of Patent: June 14, 2011Assignee: Celera CorporationInventors: Bruno Domon, Aiqun Li, Tao He, Ian McCaffery
-
Patent number: 7947451Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: December 1, 2008Date of Patent: May 24, 2011Assignee: Celera CorporationInventors: Yonghong Li, Ann Begovich, Monica Chang, Michele Cargill, Steven Schrodi
-
Patent number: 7910303Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: October 19, 2007Date of Patent: March 22, 2011Assignees: Celera Corporation, Lieden University Medical Center (LUMC)Inventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
-
Patent number: 7892760Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: GrantFiled: November 19, 2008Date of Patent: February 22, 2011Assignee: Celera CorporationInventors: Charles Birse, Marcia Lewis, Steve Ruben, Mehdi Mesri
-
Patent number: 7863021Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.Type: GrantFiled: September 4, 2008Date of Patent: January 4, 2011Assignee: Celera CorporationInventors: Steven J. Schrodi, Ann B. Bogovich
-
Patent number: 7842291Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: May 22, 2007Date of Patent: November 30, 2010Assignee: Celera CorporationInventors: Steve Ruben, Paul A. Moore, Tao He, Candy N. Lee, Karen Van Orden, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
-
Patent number: 7842466Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: GrantFiled: February 19, 2008Date of Patent: November 30, 2010Assignee: Celera CorporationInventors: Yeounjin Kim, Tao He, Steve Ruben
-
Patent number: 7842467Abstract: The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.Type: GrantFiled: May 29, 2008Date of Patent: November 30, 2010Assignee: Celera CorporationInventors: Jenny Heidbrink, Steve Ruben, Charles E. Birse, Tao He
-
Patent number: 7833706Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: January 30, 2004Date of Patent: November 16, 2010Assignee: Celera CorporationInventors: Ann Bethea Begovich, Victoria Elizabeth Hope Carlton, Steven Jon Schrodi, Heather Camille Alexander
-
Patent number: 7820380Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: May 9, 2005Date of Patent: October 26, 2010Assignee: Celera CorporationInventor: Hongjin Huang
-
Patent number: 7816083Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: May 1, 2008Date of Patent: October 19, 2010Assignee: Celera CorporationInventors: Andrew Grupe, Yonghong Li
-
Patent number: 7811794Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: March 18, 2004Date of Patent: October 12, 2010Assignee: Celera CorporationInventors: Michele Cargill, Ann Bethea Begovich, Heather Camille Alexander
-
Patent number: 7807392Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung cancer (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: GrantFiled: September 28, 2007Date of Patent: October 5, 2010Assignee: Celera CorporationInventors: Bruno Domon, Elizabeth Joseloff, Aiqun Li, Tao He
-
Patent number: 7799530Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: September 22, 2006Date of Patent: September 21, 2010Assignee: Celera CorporationInventors: Olga Iakoubova, James Devlin